Skip to main content

Home/ Dr. Goodyear/ Group items tagged Mayo

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
star yu

Síndrome nefrótico sin respuesta a 40 mg de prednisona - 0 views

www.hospitalrenal.com/...550.html

síndrome nefrótico tratamientoEl

shared by star yu on 07 Feb 15 - No Cached
  • star yu on 07 Feb 15
     
    Mi hijo de 5 años hija fue diagnosticada con síndrome nefrótico de mayo de 2013.No hay respuesta a tomar 40 mg diarios de prednisona. La biopsia mostró FSGS .Qué debemos hacer ahora? De acuerdo con la descripción de este caso médico, los médicos del Hospital de Enfermedades del Riñón Shijiazhuang dan las siguientes sugerencias.
  • star yu on 08 Feb 15
     
    Mi hijo de 5 años hija fue diagnosticada con síndrome nefrótico de mayo de 2013.No hay respuesta a tomar 40 mg diarios de prednisona. La biopsia mostró FSGS .Qué debemos hacer ahora? De acuerdo con la descripción de este caso médico, los médicos del Hospital de Enfermedades del Riñón Shijiazhuang dan las siguientes sugerencias.
Nathan Goodyear

Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A Population-B... - 0 views

www.mayoclinicproceedings.org/...abstract

oophorectomy menopause chronic disease of aging women hormones

shared by Nathan Goodyear on 04 Oct 16 - No Cached
  • Nathan Goodyear on 04 Oct 16
     
    For most women, the practice of pre-menopausal, preventative removal of ovaries should be no more.  Evidence does not support a reduction in ovarian cancer; but, it does support an increased risk of depression, hyper lipidemia, cardiac arrhythmia, CAD, arthritis, asthma, COPD, and asthma.
Nathan Goodyear

High School Football and Risk of Neurodegeneration: A Community-Based Study - Mayo Clin... - 0 views

www.mayoclinicproceedings.org/...fulltext

TBI football traumatic brain injury brain brain injury brain health neurodegenerative disease

shared by Nathan Goodyear on 16 Dec 16 - No Cached
  • Nathan Goodyear on 16 Dec 16
     
    Study finds increased TBI in high school football players, but not an increase in neurodegenerative disease.
Nathan Goodyear

Autonomic tone as a cardiovascular risk facto... [Mayo Clin Proc. 2002] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...11794458

HRV heart rate variability heart rate variability

shared by Nathan Goodyear on 30 Apr 12 - No Cached
  • Nathan Goodyear on 30 Apr 12
     
    Review of benefits of Heart Rate Variability testing (HRV).
Nathan Goodyear

High Exercise Capacity Attenuates the Risk of Early Mortality After a First Myocardial ... - 0 views

www.mayoclinicproceedings.org/...abstract

exercise heart attack myocardial infarction heart health heart disease CVD

shared by Nathan Goodyear on 02 Feb 16 - No Cached
  • Nathan Goodyear on 02 Feb 16
     
    exercise improves survival after heart attack.
Nathan Goodyear

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratificatio... - 0 views

www.ncbi.nlm.nih.gov/...PMC2931618

Waldenstrom lymphoma "waldenstrom's macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    A must read on waldenstrom's macroglobulinemia.
Nathan Goodyear

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy - Mayo Clinic Proc... - 0 views

www.mayoclinicproceedings.org/...fulltext

testosterone therapy testosterone replacement therapy DVT PE VTE venous thromboembolism testosterone

shared by Nathan Goodyear on 30 Jul 17 - No Cached
  • Nathan Goodyear on 30 Jul 17
     
    Venous thromboembolism found not be associated with prior Testosterone therapy in men.
Nathan Goodyear

Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2... - 0 views

www.nature.com/...s41698-017-0044-8

cancer cancer stem cells liver cancer vitamin C IV vitamin C oncology

shared by Nathan Goodyear on 30 Jan 18 - No Cached
  • Chen et al. have revealed that ascorbate at pharmacologic concentrations (0.3–20 mM) achieved only by intravenously (i.v.) administration selectively kills a variety of cancer cell lines in vitro, but has little cytotoxic effect on normal cells.
  • Ascorbic acid (the reduced form of vitamin C) is specifically transported into cells by sodium-dependent vitamin C transporters (SVCTs)
  • SVCT-1 is predominantly expressed in epithelial tissues
  • ...41 more annotations...
  • whereas the expression of SVCT-2 is ubiquitous
  • differential sensitivity to VC may result from variations in VC flow into cells, which is dependent on SVCT-2 expression.
  • high-dose VC significantly impaired both the tumorspheres initiation (Fig. 4d, e) and the growth of established tumorspheres derived from HCC cells (Fig. 4f, g) in a time-dependent and dose-dependent manner.
  • Hepatocellular carcinoma (HCC)
  • The antioxidant, N-acetyl-L-cysteine (NAC), preventing VC-induced ROS production (a ROS scavenger), completely restored the viability and colony formation among VC-treated cells
  • DNA double-strand damage was found following VC treatment
  • DNA damage was prevented by NAC
  • Interestingly, the combination of VC and cisplatin was even more effective in reducing tumor growth and weight
  • Consistent with the in vitro results, stemness-related genes expressions in tumor xenograft were remarkably reduced after VC or VC+cisplatin treatment, whereas conventional cisplatin therapy alone led to the increase of CSCs
  • VC is one of the numerous common hepatoprotectants.
  • Interestingly, at extracellular concentrations greater than 1 mM, VC induces strong cytotoxicity to cancer cells including liver cancer cells
  • we hypothesized that intravenous VC might reduce the risk of recurrence in HCC patients after curative liver resection.
  • Intriguingly, the 5-year disease-free survival (DFS) for patients who received intravenous VC was 24%, as opposed to 15% for no intravenous VC-treated patients
  • Median DFS time for VC users was 25.2 vs. 18 months for VC non-users
  • intravenous VC use is linked to improved DFS in HCC patients.
  • In this study, based on the elevated expression of SVCT-2, which is responsible for VC uptake, in liver CSCs, we revealed that clinically achievable concentrations of VC preferentially eradicated liver CSCs in vitro and in vivo
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      the authors here made similar mistakes to the Mayo authors i.e. under doses here in this study.  They dosed at only 2 grams IVC.  A woefully low dose of IVC.
  • Additionally, we found that intravenous VC reduced the risk of post-surgical HCC progression in a retrospective cohort study.
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      positive results despite a low dose used.
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      Their comfort zone was 1mM.  They should have targeted 20-40 mM.
  • Three hundred thirty-nine participants (55.3%) received 2 g intravenous VC for 4 or more days after initial hepatectomy
  • As the key protein responsible for VC uptake in the liver, SVCT-2 played crucial roles in regulating the sensitivity to ascorbate-induced cytotoxicity
  • we also observed that SVCT-2 was highly expressed in human HCC samples and preferentially elevated in liver CSCs
  • SVCT-2 might serve as a potential CSC marker and therapeutic target in HCC
  • CSCs play critical roles in regulating tumor initiation, relapse, and chemoresistance
  • we revealed that VC treatment dramatically reduced the self-renewal ability, expression levels of CSC-associated genes, and percentages of CSCs in HCC, indicating that CSCs were more susceptible to VC-induced cell death
  • as a drug for eradicating CSCs, VC may represent a promising strategy for treatment of HCC, alone or particularly in combination with chemotherapeutic drugs
  • In HCC, we found that VC-generated ROS caused genotoxic stress (DNA damage) and metabolic stress (ATP depletion), which further activated the cyclin-dependent kinase inhibitor p21, leading to G2/M phase cell cycle arrest and caspase-dependent apoptosis in HCC cells
  • we demonstrated a synergistic effect of VC and chemotherapeutic drug cisplatin on killing HCC both in vitro and in vivo
  • Intravenous VC has also been reported to reduce chemotherapy-associated toxicity of carboplatin and paclitaxel in patients,38 but the specific mechanism needs further investigation
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      so, exclude the benefit to patients until the exact mechanism of action, which will never be fully elicited?!?!?
  • Our retrospective cohort study also showed that intravenous VC use (2 g) was related to the improved DFS in HCC patients after initial hepatectomy
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      Terribly inadequate dose.  Target is 20-40 mM which other studies have found occur with 50-75 grams of IVC.
  • several clinical trials of high-dose intravenous VC have been conducted in patients with advanced cancer and have revealed improved quality of life and prolonged OS
  • high-dose VC was not toxic to immune cells and major immune cell subpopulations in vivo
  • high recurrence rate and heterogeneity
  • tumor progression, metastasis, and chemotherapy-resistance
  • SVCT-2 was highly expressed in HCC samples in comparison to peri-tumor tissues
  • high expression (grade 2+/3+) of SVCT-2 was in agreement with poorer overall survival (OS) of HCC patients (Fig. 1c) and more aggressive tumor behavior
  • SVCT-2 is enriched in liver CSCs
  • these data suggest that SVCT-2 is preferentially expressed in liver CSCs and is required for the maintenance of liver CSCs.
  • pharmacologic concentrations of plasma VC higher than 0.3 mM are achievable only from i.v. administration
  • The viabilities of HCC cells were dramatically decreased after exposure to VC in dose-dependent manner
  • VC and cisplatin combination further caused cell apoptosis in tumor xenograft
  • These results verify that VC inhibits tumor growth in HCC PDX models and SVCT-2 expression level is associated with VC response
  • qPCR and IHC analysis demonstrated that expression levels of CSC-associated genes and percentages of CSCs in PDXs dramatically declined after VC treatment, confirming the inhibitory role of VC in liver CSCs
  • Nathan Goodyear on 30 Jan 18
     
    IV vitamin C in vitro and in vivo found to "preferentially" eradicate cancer stem cells.  In addition, IV vitamin C was found to be adjunctive to chemotherapy, found to be hepatoprotectant.  This study also looked at SVCT-2, which is the transport protein important in liver C uptake.
1 - 12 of 12
Showing 20▼ items per page